Novo Nordisk A/S - share repurchase programme
January 27, 2025 08:05 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
January 24, 2025 05:19 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once...
Novo Nordisk A/S - share repurchase programme
January 20, 2025 09:32 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
January 17, 2025 07:11 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial...
Novo Nordisk A/S - share repurchase programme
January 13, 2025 08:52 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
January 08, 2025 06:30 ET
|
Novo Nordisk A/S
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular...
Novo Nordisk A/S - share repurchase programme
December 20, 2024 07:47 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
December 20, 2024 05:41 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial...
Novo Nordisk A/S - share repurchase programme
December 16, 2024 07:52 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...